(Modified) PTO/SB/21 (6-98) Approved for through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please	type a plus sign (+) inside the box ->	+
OIPE	Under the Paperwork Reduction Act of 1 valid OMB control number.	995,

no persons are required to respond to a collection of information unless it displays a

T	R	A	N	S	M		T	T	A	L
			F	0	R	N	Л			

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/721,507
Filing Date	November 22, 2000
First Named Inventor	Joseph A. Affholter
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	02-104244US

	ENCLOSURES (check all that app	ofy)				
Fee Transmittal Form	Assignment Papers (for an Application) Drawing(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences				
Amendment / Response After Final	Licensing-related Papers Petition Routing Slip (PTO/SB/69) and Accompanying Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information				
Affidavits/declaration(s	Petition to Convert to a Provisional Application	Status Letter				
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address	Additional Enclosure(s) (please identify below):				
Express Abandonment Reque	Terminal Disclaimer Small Entity Statement	receipt acknowledgment postcard				
Certified Copy of Priority Document(s) Response to Missing Parts/	Authorization to Charge Deposit Account	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time				
Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks					
SIGNA	ATURE OF APPLICANT, ATTORNEY, OR	AGENT				
Firm or Individual name Jonathan Alan Quine Reg. No. 41,261 The Law Offices of Jonathan Alan Quine Reg. No. 41,261 The Law Offices						
Signature Anuth	Kh Quin					
Date January 1	., 2001					
	CERTIFICATE OF MAILING					
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an						

envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: January 11. 2001

Date

January 11, 2001

Alexandra Allison

Typed or printed name

Signature

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addresse

Assistant Commissioner for Patents, Washington, D.C. 20231, January 11, 2001

The Law Offices of Jonathan Alan Quine

Alexandra Allison





Attorney Docket No. 02-104244US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joseph A. Affholter, et al.

Application No.: 09/721,507

Filed: November 22, 2000

For: Single-Stranded Nucleic acid Template-Mediated recombination and

nucleic acid fragment isolation

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached PTO-1449 forms are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/656,549 filed September 6, 2000. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/656,549 filed September 6, 2000 are not provided. However the applicants will gladly provided fresh copies of any references requested by the Examiner. It is respectfully requested that the cited information on the previously submitted 1449 forms

Application No.: 09/721,507

Page 2



for application USSN 09/656,549 filed September 6, 2000 be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Jonathan A. Quine Reg. No. 41,261

The Law Offices of Jonathan Alan Quine

P.O. Box 458

Alameda, CA 94501 Tel: (510) 337-7871 Fax: (510) 337-7877

JAQ:afa



(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

Complete if Known

99/656549 09 / 7 21, 507

September 6, 2000

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

O I P E

(use as many sheets as necessary)

				S. PATENT DOCUMENT		Pages, Columnia, Aines II
Examiner Initials	Cite No.	U.S. Patent Do Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passage or Relevant Figures Appe
	AA	5,512,463		Stemmer	04-30-1996	
	AB	5,514,588		Varadaraj	05-07-1996	
	AC	5,605,793		Stemmer	02-25-1997	
	AD	5,763,239		Short et al.	06-09-1998	
	ΑE	5,789,228		Lam et al.	08-04-1998	
	AF	5,811,238		Stemmer et al.	09-22-1998	
	AG	5,814,473	·	Warren et al.	09-29-1998	
	АН	5,824,469		Horwitz et al.	10-20-1998	
	ΑI	5,830,696		Short	11-03-1998	
	AJ	5,830,721		Stemmer et al.	11-03-1998	
	AK	5,834,252		Stemmer et al.	11-10-1998	
	AL	5,837,458		Minushull et al.	11-17-1998	
	AM	5,866,363		Pieczenik	02-02-1999	
	AN	5,876,997		Kretz	03-02-1999	
	AO	5,925,749		Mathur, et al.	07-20-1999	
	AP	5,928,905		Stemmer, et al.	07-27-1999	
	AQ	5,939,250		Short, Jay M.	08-17-1999	
	AR	5,939,300		Robertson, et al.	08-17-1999	
	AS	5,942,430		Robertson, et al.	08-24-1999	
	AT	5,948,666		Callen, et al.	09-07-1999	
	AU	5,958,672		Short, Jay M.	09-28-1999	
	AV	5,958,751		Murphy, et al.	09-28-1999	
	AW	5,962,258		Mathur, et al.	10-05-1999	
	AX	5,962,283		Warren et al.	10-05-1999	
	AY	5,965,408		Short, Jay M.	10-12-1999	
	AZ	5,985,646		Murphy, et al.	11-16-1999	
	ВА	6,001,574		Short et al.	12-14-1999	
xamine ignature	I			Da Co	te nsidered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPOFROM PARENTIAN 1 6 2001

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	MANERIC Complete if Known			
	Application Number	- 09/656549 09/721,507		
INFORMATION DISCLOSURE	Filing Date	September 6, 2000		
STATEMENT BY APPLICANT	First Named Inventor	Joseph A. Affholter		
	Group Art Unit	1645		
	Examiner Name	Unassigned		
(use as many sheets as necessary)	Attorney Docket Number	02-104240US		

	BB	6,004,788	Short	12-21-1999	
ı	вс	6,030,779	Short	02-29-2000	
1	BD	6,054,267	Short	04-25-2000	
E	BE	6,117,679	Stemmer	09-12-2000	
E	BF	6,096,548	Stemmer	08-01-2000	
E	BG	6,132,970	Stemmer	10-17-2000	

				FOREIG	N PATENT DOCUMEN			
Examin er Initials	Cite No.	Office	Foreign Patent Docui	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	вн	wo	97/07205		Novo Nordisk A/S	02-27-1997		
	ВІ	wo	97/20078		Affymax Technologies	06-05-1997		
	BJ	wo	97/25410		Novo Nordisk A/S	07-17-1997		
	ВК	wo	97/35957		Maxygen, Inc.	10-02-1997		
	BL	wo	97/35966		Maxygen, Inc.	10-02-1997		
	ВМ	wo	97/44361		Recombinant Biocatalysis Inc.	11-27-1997		
	BN	wo	97/48416		Recombinant Biocatalysis, Inc.	12-24-1997		
	во	wo	97/48717		Recombinant Biocatalysis Inc	12-24-1997		
	ВР	wo	97/48794		Recombinant Biocatalysis Inc	12-24-1997		
	BQ	wo	98/00526		Recombinant Biocatalysis Inc	01-08-1998		
	BR	wo	98/01581		Recombinant Biocatalysis Inc	01-15-1998		
	BS	wo	98/13485		Maxygen, Inc.	04-02-1998		
	вт	wo	98/13487		Maxygen, Inc.	04-02-1998		
	BU	wo	98/24799		Diversa Corp.	06-11-1998		
	BV	wo	98/27230		Maxygen, Inc.	06-25-1998		

Examiner	Date	1
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY PROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

RADERAR C	omplete if Known						
Application Number	09/656549 09 721, 807						
Filing Date	September 6, 2000						
First Named Inventor	Joseph A. Affholter						
Group Art Unit	1645						
Examiner Name	Unassigned						
Attorney Docket Number	02-104240US						

BW	wo	98/28416	Novo Nordisk A/S	07-02-1998	
ВХ	wo	98/31837	Maxygen, Inc.	07-23-1998	
BY	wo	98/36080	Maxygen, Inc.	08-20-1998	
BZ	wo	98/41622	Novo Nordisk A/S	09-24-1998	
CA	wo	98/41623	Novo Nordisk A/S	09-24-1998	
СВ	wo	98/41653	Novo Nordisk A/S	09-24-1998	
СС	wo	98/42832	California Institute of Technology	10-01-1998	
CD	wo	98/48034	Diversa Corp.	10-29-1998	
CE	wo	98/58085	Diversa Corp.	12-23-1998	
CF	wo	99/07837	Diversa Corp.	02-19-1999	
CG	wo	99/08539	Diversa Corp.	02-25-1999	
СН	wo	99/10472	Diversa Corp.	03-04-1999	
CI	wo	99/10539	Diversa Corp.	03-04-1999	
CJ	wo	99/19518	Diversa Corp.	04-22-1999	
СК	EP	0911396A2	Maxygen, Inc.	04-28-1999	
CL	wo	99/21979	Maxygen, Inc.	05-06-1999	
СМ	EP	0911396A3	Maxygen, Inc.	05-06-1999	
CN	wo	99/23107	Maxygen, Inc.	05-14-1999	
СО	wo	99/23236	Diversa Corp.	05-14-1999	
СР	EP	0934999A1	Maxygen, Inc.	08-11-1999	
CQ	wo	99/41368	Maxygen, Inc.	08-19-1999	
CR	wo	99/41369	Maxygen, Inc.	08-19-1999	
cs	wo	99/41383	Maxygen, Inc.	08-19-1999	
СТ	wo	99/41402	Maxygen, Inc.	08-19-1999	
CU	wo	99/45154	Diversa Corp.	09-10-1999	
 CV	wo	99/57128	Maxygen, Inc.	11-11-1999	
 cw	wo	99/65927	Maxygen, Inc,	12-23-1999	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



JAN 1 6 2001

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Co Co	omplete if Known
Application Number	09/656549 09/721,507
Filing Date	September 6, 2000
First Named Inventor	Joseph A. Affholter
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	02-104240US

Examin er Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	CX Chang, C., et al. (1999) "Evolution of a cytokine using DNA family shuffling." Nature Biotechnology 17:793-797.					
	CY	Christians, F.C. et al., (1999) "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling." <i>Nature Biotechnology</i> 17:259-264.				
	CZ	Crameri et al., (1993) "10(20)-Fold aptamer library amplification without gel purification," Nuc. Acids Res. 21(18):4410.				
	DA	Crameri, A. & Stemmer W.P.C. (1995) "Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes." <u>Biotechniques</u> 18:194-195.				
	DB	Crameri, A. et al. (1996) "Improved green fluorescent protein by molecular evolution using DNA shuffling." Nature Biotechnology 14:315-319.				
	DC	Crameri, A. et al. (1996) "Construction and evolution of antibody-phage libraries by DNA shuffling." Nature Medicine 2:100-103.				
	DD	Crameri, A. et al., (1997) "Molecular evolution of an arsenate detoxification pathway by DNA shuffling." <i>Nature Biotechnology</i> 15:436-438				
	DE	Crameri, A. et al., (1998) "DNA shuffling of a family of genes from diverse species accelerates directed evolution." <i>Nature</i> 391:288-291.				
С	OF	Gates, C.M. et al., (1996) "Affinity selective isolation of ligands from peptide libraries through display on a lac repressor 'headpiece dimer'. <i>Journal of Molecular Biology</i> 255:373-386.				
С)G	Minshull, J., Stemmer, W.P.C. (1999) "Protein evolution by molecular breeding." <u>Current</u> <u>Opinion in Chemical Biology</u> 3:284-290.				
C	ЭН	Ness, J. et al., (1999) "DNA shuffling of subgenominc sequences of subtilisin." <i>Nature Biotechnology</i> 17:893-896.				
С)I	Patten, P.A. et al., (1997) "Application of DNA Shuffling to Pharmaceuticals and Vaccines." <u>Current Opinion in Biotechnology</u> 8:724-733.				
C	ΟĴ	Stemmer, W.P.C. (1994) "DNA Shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution." <i>PNAS</i> 91:10751				
C	Ж	Stemmer, W.P.C. (1994) "Rapid evolution of a protein in vitro by DNA shuffling." <u>Nature</u> 370:389-391.				
С	DL	Stemmer, W.P.C. (1995) "The Evolution of Molecular Computation." Science 270:1510				
C	M	Stemmer, W.P.C. (1995) "Searching Sequence Space." Bio/Technology 13:549-553.				
С	N	Stemmer, W.P.C. (1996) "Sexual PCR and Assembly PCR." In: <u>The Encyclopedia of Molecular Biology</u> . VCH Publishers, New York. pp. 447-457.				
xaminer	-	Date				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



JAN 1 6 2001

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Complete if Known Substitute for form 1449A-B/PTO Application Number 09/656549 09 7-21,507 September 6, 2000 Filing Date INFORMATION DISCLOSURE First Named Inventor Joseph A. Affholter STATEMENT BY APPLICANT Group Art Unit 1645 Unassigned **Examiner Name** (use as many sheets as necessary) 02-104240US Attorney Docket Number

DO	Stemmer, W.P.C. & Soong, N.W. (1999) "Molecular breeding of viruses for targeting and other clinical properties." <u>Tumor Targeting</u> 4:59-62.
DP	Zhang, J. et al., (1997) "Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening." <i>Proceedings of the National Academy of Sciences, USA</i> 94:4504-4509.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

JAN 1 6 2001

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	TRADEMARY C	omplete if Known
	Application Number	09/656549 09 721,507
INFORMATION DISCLOSURE	Filing Date	September 6, 2000
STATEMENT BY APPLICANT	First Named Inventor	Joseph A. Affholter
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	02-104240US

U.S. PATENT DOCUMENTS						
		U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal

	-					

			Foreign Patent Docu	ument		Date of Publication	Pages, Columns, Lines,	Ι_
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	<u> </u>
		wo	00/00632		Phylos, Inc.	01-06-2000		
		wo	00/09679		Proteus	02-24-2000		L
								_
								L

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-		ļ
		Cite Include name of the author (in CAPITAL I ETTERS) title of the article (when appropriate), title of the item (book, magazine, journal,

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.